Disease Domain | Count |
---|---|
Nervous System Diseases | 14 |
Infectious Diseases | 4 |
Endocrinology and Metabolic Disease | 3 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 36 |
Vaccine | 1 |
Recombinant polypeptide | 1 |
Target |
Mechanism μ opioid receptor agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date07 Aug 2020 |
Target |
Mechanism μ opioid receptor agonists |
Originator Org. |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date12 Jul 1996 |
Target |
Mechanism fungal CYP51A1 inhibitors |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. ES |
First Approval Date10 Mar 1995 |
Start Date13 Mar 2024 |
Sponsor / Collaborator |
Start Date03 Jan 2024 |
Sponsor / Collaborator |
Start Date20 Nov 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Fenofibrate ( PPARα ) | Hypertriglyceridemia More | Approved |
Clonazepam ( GABAA receptor ) | Epilepsy More | Approved |
Etomidate ( GABAA receptor ) | Anesthesia More | Approved |
Flutrimazole ( fungal CYP51A1 ) | Mycoses More | Approved |
Pipemidic Acid Hydrate ( Bacterial DNA gyrase ) | Urinary Tract Infections More | Approved |